Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, CYTK, MAZE, LYEL, XENE, and represent 97.14% of Foresite Capital Management IV's stock portfolio.
  • Added to shares of these 2 stocks: CYTK (+$25M), PHVS (+$9.2M).
  • Started 1 new stock position in CYTK.
  • Reduced shares in these 2 stocks: MAZE (-$41M), KURA.
  • Sold out of its position in KURA.
  • Foresite Capital Management IV was a net seller of stock by $-12M.
  • Foresite Capital Management IV has $183M in assets under management (AUM), dropping by 47.51%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Foresite Capital Management IV holds 6 positions in its portfolio as reported in the September 2025 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 65.3 $119M +8% 4.8M 24.95
 View chart
Cytokinetics (CYTK) 13.8 $25M NEW 458k 54.96
 View chart
Maze Therapeatics (MAZE) 7.4 $14M -75% 523k 25.93
 View chart
Lyell Immunopharma (LYEL) 7.1 $13M 800k 16.24
 View chart
Xenon Pharmaceuticals (XENE) 3.5 $6.4M 160k 40.15
 View chart
Relay Therapeutics (RLAY) 2.9 $5.2M 1.0M 5.22
 View chart

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings